NASHVILLE, Tenn., April 28 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq:CPIX - News) today announced it has entered into an exclusive agreement with Alveda Pharmaceuticals Inc. (Alveda Pharma), a Toronto-based specialty pharmaceutical company, for the commercialization of Caldolor® (ibuprofen) Injection in Canada. Designed to treat pain and fever in the hospital setting, Caldolor was approved by the U.S. Food and Drug Administration (FDA) and launched by Cumberland in the United States in 2009.
